Surgical heart valves are bioprosthesis, such as RESILIA tissue, offer patients a way to think differently about life after surgery.
A key challenge with pericardial tissue is structural valve deterioration (SVD), much of which is due to calcium buildup. RESILIA tissue is transformed to resist calcification differently.
For more clinical information on the performance of RESILIA tissue, visit the Inspiring Results page.
COMMENCE aortic clinical trial
Clinically stable gradients, high rates of freedom from mortality through 7 years, as well as high rates of freedom from reintervention and structural valve deterioration (SVD) through 7 years
Preclinical juvenile sheep model study
Significant improvement of anti-calcification properties in test valves compared to control.1
** RESILIA tissue tested against tissue from commercially available bovine pericardial valves from Edwards in a juvenile sheep model. Flameng, et al.J Thorac Cardiovasc Surg 2015;149:340-5
Clinically stable hemodynamics and one incidence of SVD through 5 years.
For patients referred for surgical valve replacement, there are now three options: mechanical valves, conventional tissue valves or RESILIA tissue valves. RESILIA tissue gives surgeons the freedom to offer a resilient tissue alternative that brings the quality-of-life benefits of tissue valves to patients.
With RESILIA tissue, patients and surgeons alike gain the freedom that comes with peace of mind. It’s knowing that Edwards Lifesciences has a proven commitment to ongoing innovation in surgical structural heart solutions, to advance the state of the art and put better outcomes within reach.
Today’s RESILIA tissue portfolio is the culmination of years of careful, deliberate development in collaboration with cardiac surgeons, innovating while building on proven technology. It represents the best of creative scientific minds coming together to address unmet needs and satisfy patient demands for better surgical options.
Explore our current RESILIA tissue products
* No clinical data are available that evaluate the long-term impact of RESILIA tissue in patients. Additional clinical data for up to 10 years of follow-up are being collected to monitor the long-term safety and performance of RESILIA tissue.
For a listing of indications, contraindications, precautions, warnings, and potential adverse events, please refer to the Instructions for Use (consult eifu.edwards.com where applicable).
